Sung Lee
Director of Finance/CFO chez VIR BIOTECHNOLOGY, INC.
Fortune : 1 M $ au 31/03/2024
Profil
Sung H.
Lee is currently the Chief Financial Officer, Secretary & Executive VP at Vir Biotechnology, Inc. He previously held positions as Vice President-Investor Relations at Gilead Sciences, Inc. from 2005 to 2019, Chief Financial Officer & Executive Vice President at Sangamo Therapeutics, Inc. from 2019 to 2021, and Chief Financial Officer at MorphoSys AG from 2021 to 2023.
Mr. Lee holds a graduate degree from the University of Southern California and an undergraduate degree from the University of California, Irvine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
VIR BIOTECHNOLOGY, INC.
0,07% | 27/03/2024 | 100 492 ( 0,07% ) | 1 M $ | 31/03/2024 |
Postes actifs de Sung Lee
| Sociétés | Poste | Début |
|---|---|---|
| VIR BIOTECHNOLOGY, INC. | Director of Finance/CFO | 27/03/2023 |
Anciens postes connus de Sung Lee
| Sociétés | Poste | Fin |
|---|---|---|
| MORPHOSYS AG | Director of Finance/CFO | 17/03/2023 |
| SANGAMO THERAPEUTICS, INC. | Director of Finance/CFO | 01/02/2021 |
| GILEAD SCIENCES, INC. | Investor Relations Contact | 31/10/2019 |
Formation de Sung Lee
| University of Southern California | Graduate Degree |
| University of California, Irvine | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| SANGAMO THERAPEUTICS, INC. | Health Technology |
| MORPHOSYS AG | Health Technology |
| VIR BIOTECHNOLOGY, INC. | Health Technology |
